TY - JOUR
T1 - Biosensing in Smart Engineered Probiotics
AU - Rottinghaus, Austin G.
AU - Amrofell, Matthew B.
AU - Moon, Tae Seok
N1 - Funding Information:
A.G.R. and M.B.A. contributed equally to this work. This work was supported by the Office of Naval Research (N00014-17-1-2611 to T.S.M.), the National Institutes of Health (1R01AT009741-01 to T.S.M.), and the National Science Foundation Graduate Research Fellowship Program (DGE-1745038 to M.B.A.).
Publisher Copyright:
© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
PY - 2020/10/1
Y1 - 2020/10/1
N2 - Engineered microbes are exciting alternatives to current diagnostics and therapeutics. Researchers have developed a wide range of genetic tools and parts to engineer probiotic and commensal microbes. Among these tools and parts, biosensors allow the microbes to sense and record or to sense and respond to chemical and environmental signals in the body, enabling them to report on health conditions of the animal host and/or deliver therapeutics in a controlled manner. This review focuses on how biosensing is applied to engineer “smart” microbes for in vivo diagnostic, therapeutic, and biocontainment goals. Hurdles that need to be overcome when transitioning from high-throughput in vitro systems to low-throughput in vivo animal models, new technologies that can be implemented to alleviate this experimental gap, and areas where future advancements can be made to maximize the utility of biosensing for medical applications are also discussed. As technologies for engineering microbes continue to be developed, these engineered organisms will be used to address many medical challenges.
AB - Engineered microbes are exciting alternatives to current diagnostics and therapeutics. Researchers have developed a wide range of genetic tools and parts to engineer probiotic and commensal microbes. Among these tools and parts, biosensors allow the microbes to sense and record or to sense and respond to chemical and environmental signals in the body, enabling them to report on health conditions of the animal host and/or deliver therapeutics in a controlled manner. This review focuses on how biosensing is applied to engineer “smart” microbes for in vivo diagnostic, therapeutic, and biocontainment goals. Hurdles that need to be overcome when transitioning from high-throughput in vitro systems to low-throughput in vivo animal models, new technologies that can be implemented to alleviate this experimental gap, and areas where future advancements can be made to maximize the utility of biosensing for medical applications are also discussed. As technologies for engineering microbes continue to be developed, these engineered organisms will be used to address many medical challenges.
KW - biocontainment
KW - biosensing
KW - diagnostic
KW - probiotic
KW - therapeutic
UR - http://www.scopus.com/inward/record.url?scp=85077888474&partnerID=8YFLogxK
U2 - 10.1002/biot.201900319
DO - 10.1002/biot.201900319
M3 - Review article
C2 - 31860168
AN - SCOPUS:85077888474
SN - 1860-6768
VL - 15
JO - Biotechnology Journal
JF - Biotechnology Journal
IS - 10
M1 - 1900319
ER -